Last checked at 5 Jul 2012 13:09
Port Erin Biopharma Investments Limited
("Port Erin" or "the Company")
Net Asset Value calculation for the third trading quarter to 30th June 2012
Jim Mellon, Chairman, commented: -
"The Net Asset Value calculation for the Company as at closing on 30th June 2012 was 9.46 pence per share, including un-invested cash of £237,391. The portfolio is valued at bid price. This represents a marginal decline from last quarter's valuation, but still maintains a satisfactory 14% gain on the initial net funds raised at inception."
| Unaudited 15 September 2011 to 30 June 2012 £ | |
Fixed Assets |
|
|
| Investments
| 2,892,182 |
Current Assets |
|
|
| Debtors: amounts owing | 9,511 |
| Uninvested cash
| 237,391 |
Current Liabilities |
|
|
| Creditors: amounts due
| (17,431) |
|
| 3,121,653 |
Capital and Reserves |
|
|
| Share Capital | 33 |
| Share Premium | 3,000,967 |
| Capital reserve - realised | 0 |
| Capital reserve - unrealised | 0 |
| Revenue reserve
| 120,653 |
| 3,121,653 | |
| ||
Shares in Issue
| 33,000,000 | |
Net Asset Value per share
| 9.46 pence | |
| Detailed Portfolio |
|
Holding | £ Value @ 30/06/12 | Portfolio % |
Arrowhead Research Corp. | 254,109 | 8.8% |
Synergy Pharmaceuticals Inc. | 242,293 | 8.4% |
Plethora Solutions Holdings | 241,045 | 8.3% |
Pfizer Inc. | 217,778 | 7.5% |
Novartis AG | 160,387 | 5.5% |
Gilead Sciences Inc. | 141,167 | 4.9% |
Astellas Pharmaceuticals Inc. | 140,607 | 4.9% |
Summit Corporation plc | 128,055 | 4.4% |
Abbott Laboratories | 119,680 | 4.1% |
Merck & Co. Inc. | 101,564 | 3.5% |
Nektar Therapeutics | 86,706 | 3.0% |
Immunocellular Therapeutics Ltd. | 85,760 | 3.0% |
H. Lundebeck A/S | 73,848 | 2.6% |
Rigel Pharmaceuticals | 72,652 | 2.5% |
Onyx Pharmaceuticals | 68,069 | 2.4% |
Medivation Inc. | 64,372 | 2.2% |
Map Pharmaceuticals Inc. | 64,138 | 2.2% |
Medivir AB-B | 63,169 | 2.2% |
Celgene Corp. | 57,508 | 2.0% |
Shire plc | 55,139 | 1.9% |
Siga Technologies Inc. | 42,121 | 1.5% |
Thershold Pharmaceuticals, Inc. | 41,406 | 1.4% |
Synta Pharmaceuticals Inc. | 40,556 | 1.4% |
Pharmathene Inc. | 37,283 | 1.3% |
Keryx Biopharmaceuticals Inc. | 34,578 | 1.2% |
Miraculins Inc. | 30,057 | 1.0% |
Biotime Inc. | 27,628 | 1.0% |
Orexigen Therapeutics, Inc. | 26,510 | 0.9% |
Methylgene Inc. | 19,648 | 0.7% |
Pacific Biosciences California Inc. | 17,460 | 0.6% |
Complete Genomics Inc. | 16,079 | 0.6% |
Polymedix Inc. | 14,215 | 0.5% |
Synergy - warrants (publicly traded) | 10,547 | 0.4% |
Loan: Ampliphi Biosciences Corp. | 64,033 | 2.2% |
Loan: Spiritus Pharmaceuticals, LLC | 32,016 | 1.1% |
2,892,182 | 100.0% |
ENDS
For further information, please contact:
Port Erin Biopharma Investments Ltd | Libertas Capital Corporate Finance Limited | Rivington Street Corporate Finance Limited |
The Company | Nomad | Broker |
Denham Eke +44 162 463 9396 | Sandy Jamieson +44 207 569 9650 | Jon Levinson +44 207 562 3350 |